OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Mesa on the Unique Characteristics of Momelotinib in Myelofibrosis

January 26th 2022

Ruben A. Mesa, MD, discusses the unique characteristics of momelotinib in myelofibrosis.

Dr. Corr on the Utilization of Molecular Profiling in Endometrial Cancer

January 26th 2022

Bradley R. Corr, MD, discusses the utilization of molecular profiling in endometrial cancer.

Dr. Osarogiagbon on Geographic Disparities in Lung Cancer

January 26th 2022

Raymond U. Osarogiagbon, MD, FACP, discusses geographic disparities in lung cancer.

Dr. Patel on Optimizing Molecular Testing for EGFR Mutations in Lung Cancer

January 26th 2022

Sandip P. Patel, MD, discusses optimizing molecular testing for EGFR mutations in lung cancer.

Dr. Barzi on the Importance of Developing Novel Therapies in Metastatic CRC

January 26th 2022

Afsaneh Barzi, MD, PhD, discusses the importance of developing novel therapies in metastatic colorectal cancer.

Dr. Woloszynska on Continued Research Efforts Investigating Racial Disparities in Prostate Cancer

January 26th 2022

Anna Woloszynska, PhD, discusses continued research efforts investigating racial disparities in prostate cancer.

Dr. Lister on Selecting Patients With Lymphoma for CAR T-Cell Therapy

January 26th 2022

John Lister, MD, discusses selecting patients with lymphoma for CAR T-cell therapy.

Dr. Singhi on the Importance of Multidisciplinary Care With Pathologists in Cancer

January 25th 2022

Aatur D. Singhi, MD, PhD, discusses the importance of facilitating multidisciplinary conversations that include pathologists in cancer care.

Dr. Graham on the Role of the Pathologist in Biomarker Testing in Breast and GI Cancers

January 25th 2022

Rondell P. Graham, MBBS, discusses the role of the pathologist in biomarker testing for patients with breast and gastrointestinal cancers.

Dr. Factor on the Lack of Standardization in Biomarker Testing in Breast and GI Cancers

January 25th 2022

Rachel E. Factor, MD, MS, discusses the lack of standardization with biomarker testing in breast and gastrointestinal cancers.

Dr. Westin on Patient-Reported Outcomes From the TRANSFORM Study in R/R LBCL

January 24th 2022

Jason R. Westin, MD,discusses the patient-reported outcome data from the phase 3 TRANSFORM study in relapsed/ refractory large B-cell lymphoma.

Dr. Westin on the 2​-Year Follow-Up of the TRANSCEND-NHL-001 Trial in R/R LBCL

January 24th 2022

Jason R. Westin, MD, discusses the 2-year follow-up data of the ongoing phase 1 TRANSCEND-NHL-001 trial in relapsed/refractory large B-cell lymphoma.

Dr. Chandra on Evaluating Biological Differences in African Americans With Prostate Cancer

January 24th 2022

Dhyan Chandra, PhD, discusses evaluating biological differences between African American and Caucasian men with prostate cancer.

Dr. Gershenson on the Results of the MILO Trial in Low-Grade Serous Ovarian Cancer

January 24th 2022

David M. Gershenson, MD, discusses the results of the phase 3 MILO trial in low-grade serous ovarian cancer.

Dr. Galsky on Clinical Trials That Addressed Key Questions in Urothelial Cancer

January 24th 2022

Matthew Galsky, MD, discusses clinical trials that addressed key questions in urothelial cancer.

Dr. Oh on the Results of the TOPAZ-1 Trial in Advanced Biliary Tract Cancer

January 22nd 2022

Do-Youn Oh, MD, PhD, discusses the results of the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.

Dr. Hong on the Efficiency of the CodeBreaK 101 Trial in KRAS G12C-Mutated CRC and Other Solid Tumors

January 22nd 2022

David S. Hong, MD, discusses the efficiency of the ongoing phase 1/2 CodeBreaK 101 trial in KRAS G12C-mutated advanced colorectal cancer and other solid tumors.

Dr. Bekaii-Saab on the Updated Results of the KRYSTAL-1 Trial in KRAS G12C+ GI Cancers

January 22nd 2022

Tanios S. Bekaii-Saab, MD, FACP, discusses the updated results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C-mutated gastrointestinal cancers, including pancreatic ductal adenocarcinoma.

Dr. LeBeau on the Potential Utility of Shark VNAR Proteins in Prostate Cancer

January 21st 2022

Aaron LeBeau, PhD, discusses the potential of shark variable domain of new antigen receptor proteins in prostate cancer.

Dr. Abrams on the Rationale for the COSMIC-021 Trial in MSS/pMMR CRC

January 21st 2022

Thomas A. Abrams, MD, discusses the rationale for the ongoing phase 1/2 COSMIC-021 trial in microsatellite stable and mismatch repair proficient colorectal cancer.

NEXT PAGE
PREVIOUS PAGE